The Ability of Biofilms Formation and the Differences of Antifungal Susceptibility Pattern between Planktonic and Biofilm Candida sp.
DOI:
https://doi.org/10.51601/ijhp.v6i2.618Abstract
Candida sp. as human body's flora causes infections and its ability to create biofilms antifungals and host immune responses cannot reach it caused resistance to broad-spectrum antifungal. In this study, the antifungal susceptibility patterns of ketoconazole, itraconazole, and fluconazole against biofilms of Candida sp. will be determined, as well as the differences in susceptibility patterns between biofilm and planktonic Candida sp. The antifungal susceptibility of clinical isolates of both planktonic and biofilm Candida sp. determine by liquid dilution methode and the intensity of biofilm formation determined by Crystal Violet methode. Of the twenty-four Candida sp., 70.8% exhibited strong biofilm intensity, while 29.2% had moderate intensity. Planktonic Candida sp. exhibited a 100%, 78.9%, and 57.9% susceptibility pattern to fluconazole, ketokonazole, and itraconazole, respectively. Meanwhile, the sensitivity percentage decreased for biofilm Candida sp., which had sensitivity values of 31.6%, 21.1%, and 31.6%, respectively. Planktonic Candida sp. had MIC values ranging from 2 to about 33 times lower than those of biofilm Candida sp. Compared to planktonic Candida sp., the susceptibility pattern of biofilms revealed a lower sensitivity percentage. Planktonic Candida sp. had an average value ratio of 1.5 to 3.1 times, whereas Biofilm Candida sp. had MIC values 2 to > 33 times higher.
Downloads
References
[1]. Eggimann P, Garbino J, Pittet D, Didier Pittet P. For personal use. Only reproduce with permission from The Lancet. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis [Internet]. 2003;3:685–703. Available from: http://infection.thelancet.com
[2]. Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility testing of candida isolates from The candida surveillance study. J Clin Microbiol. 2010;48(4):1270–5.
[3]. Pierce CG, Uppuluri P, Tummala S, Lopez-Ribot JL. A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp. 2010;(44):1–4.
[4]. Ramage G, VandeWalle K, Wickes BL, López-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001;18(4):163–70.
[5]. Sharvari SA, Chitra PG. Evaluation of different detection methods of biofilm formation in clinical isolates of Staphylococci. Int J Pharma Bio Sci. 2012;3(4):724–33.
[6]. Srihartati E. Uji Kepekaan Antijamur Spesies Candida dengan Metode Mikrodilusi pada Kandidiasis Vulvovaginalis ( Sensitivity Test of Antifungal to Candida sp . Using Microdelution Methods in Vulvovaginal Candidiasis ). 2010;1–2.
[7]. Mursinah, Ibrahim F WM. Profil Candida penyebab kandidemia dan pola kepekaan terhadap antijamur pada pasien kritis di RSCM. J Biotek Medisiana Indones. 2016;5:105–11.
[8]. Agustina F. Pola Kepekaan Isolat Candida albicans dari Lesi Kandidosis Kutis Terhadap Ketokonazol, Itrakonazol dan Flukonazol. 2010.
[9]. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20(9):557–71.
[10]. Robbins N, Caplan T, Cowen LE. Molecular Evolution of Antifungal Drug Resistance. Annu Rev Microbiol. 2017;71:753–75.
[11]. Bujdáková H, Kulková N, Černáková L. Susceptibility to caspofungin and fluconazole and Als1/Als3 gene expression in biofilm and dispersal cells of Candida albicans. Arh Hig Rada Toksikol. 2012;63(4):497–503.
[12]. Lee J-H, Kim Y-G, Kim Y, Lee J. Antifungal and antibiofilm activities of chromones against nine Candida species . Microbiol Spectr. 2023;11(6):1–13.
[13]. Arastehfar A, Carvalho A, Hong Nguyen M, Hedayati MT, Netea MG, Perlin DS, et al. Covid-19-associated candidiasis (Cac): An underestimated complication in the absence of immunological predispositions? J Fungi. 2020;6(4):1–13.
[14]. Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence [Internet]. 2017;8(3):352–8. Available from: http://dx.doi.org/10.1080/21505594.2016.1247140
[15]. Kaur J, Nobile CJ. Antifungal drug-resistance mechanisms in Candida biofilms. Curr Opin Microbiol [Internet]. 2023;71:102237. Available from: https://doi.org/10.1016/j.mib.2022.102237
[16]. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother. 1995;39(9):2128–31.
[17]. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–94.
[18]. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73:i4–13.
[19]. Bassetti M, Righi E, Montravers P, Cornely OA. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018;73:i14–25.
[20]. Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. Int J Antimicrob Agents [Internet]. 2017;50(3):318–24. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2017.05.019
[21]. Rodrigues ML, Nosanchuk JD. Fungal Diseases as Neglected Pathogens: A Wake-Up Call to Public Health Officials. Adv Clin Immunol Med Microbiol COVID-19, Big Data. 2021;399–411.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Inayati Inayati, Praseno Praseno, Mustofa Mustofa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
